



#### **Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)**

The author has stipulated different CC terms to the standard license on ResearchOnline under the following terms:

- **Attribution** — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- **NonCommercial** — You may not use the material for commercial purposes.
- **NoDerivatives** — If you remix, transform, or build upon the material, you may not distribute the modified material.
- **No additional restrictions** — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Citation: Seaman, K, Sanfilippo F, Bulsara M, Roughead L, Kemp-Casey A, Bulsara C, Watts GF, Preen D. Predictors of ceasing or reducing statin medication following a large increase in the consumer co-payment for medications: a retrospective observation study. Public Health Res Pract. 2019; Online early publication. <https://doi.org/10.17061/phrp29121905>

## Contents – Supplementary Tables

Table 1A: Unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for cessation compared with continuation of therapy among individuals dispensed a statin in 2005 stratified by beneficiary status .....	3
Table 2A: Unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for reduction compared with continuation of therapy among individuals dispensed a statin in 2005 stratified by beneficiary status. ....	5

Table 1A: Unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for cessation compared with continuation of therapy among individuals dispensed a statin in 2005 stratified by beneficiary status.

Demographic and clinical characteristics	Cessation of therapy (6 months of no dispensings in 2005)		
	Unadjusted OR (95%CI)	Adjusted OR (95% CI) – General patients	Adjusted OR (95% CI) – Concessional patients
Age:			
40 & below	<b>2.79 (2.39-3.25)</b>	1.47(0.90-2.38)	<b>2.41 (1.91-3.06)</b>
41 to 50	<b>1.77 (1.59-1.98)</b>	1.07 (0.68-1.70)	<b>1.89 (0.61-2.21)</b>
51 to 60	<b>1.28 (1.16-1.41)</b>	0.99 (0.63-1.56)	1.15 (1.02-1.30)
61 to 70	<b>0.80 (0.72-0.88)</b>	0.79 (0.50-1.25)	0.91 (0.81-1.01)
71 to 80	<b>0.72 (0.65-0.80)</b>	0.85 (0.51-1.40)	<b>0.84 (0.76-0.94)</b>
Above 80	1	1	1
Sex:			
Female	1.01 (0.96-1.06)	1.06 (0.97-1.16)	1.02 (0.96-1.09)
Male	1	1	1
Socio-economic disadvantage:			
Most (1)	1.05 (0.97-1.15)	1.20 (1.01-1.44)	1.06 (0.94-1.18)
2	0.98 (0.91-1.05)	1.08 (0.93-1.25)	1.07 (0.96-1.18)
3	<b>0.89 (0.83-0.95)</b>	1.11 (0.98-1.26)	0.92 (0.83-1.01)
4	1.00 (0.93-1.08)	1.13 (1.01-1.27)	0.99 (0.90-1.09)
Least (5)	1	1	1
Unknown	1.09(0.90-1.33)	1.12 (0.85-1.46)	0.91 (0.66-1.27)
Remoteness			
Major cites	1	1	1
Inner regional	<b>0.85 (0.80-0.91)</b>	<b>0.72 (0.63-0.83)</b>	0.97 (0.89-1.05)
Outer regional	1.00 (0.93-1.08)	0.90 (0.78-1.03)	0.97 (0.87-1.07)
Remote	1.09 (0.93-1.28)	0.85 (0.67-1.08)	1.16 (0.93-1.45)
Very remote	<b>1.64 (1.26-2.14)</b>	1.04 (0.69-1.58)	<b>1.80 (1.24-2.59)</b>
Unknown	0.91 (0.37-2.23)	1.06 (0.37-3.05)	0.39 (0.05-2.96)
Previous IHD (2000-2004):			
No	<b>1.36 (1.24-1.48)</b>	1.20 (0.95-1.53)	1.15 (1.01-1.31)
Yes	1	1	1
Previous Stroke (2000-2004):			
No	1.14 (0.91-1.44)	0.93 (0.55-1.59)	1.23 (0.95-1.60)
Yes	1	1	1
Previous CARP (2000-2004):			
No	<b>1.57 (1.38-1.81)</b>	<b>1.51 (1.09-2.10)</b>	<b>1.35 (1.10-1.66)</b>
Yes	1	1	1

Previous Statin Usage in 2002 and 2003:			
No	<b>3.36 (3.17-3.55)</b>	<b>3.02 (2.76-3.32)</b>	<b>3.50 (3.23-3.78)</b>
Yes	1	1	1
Beneficiary Status:			
Concessional	1	-	-
General	<b>1.60 (1.52-1.69)</b>	-	-
Cardiovascular Medication in 2004			
Yes	1	1	1
No	<b>1.49 (1.41-1.56)</b>	<b>1.36 (1.24-1.50)</b>	<b>1.33 (1.23-1.44)</b>
Diabetic Medication in 2004			
Yes	1	1	1
No	0.98 (0.92-1.04)	0.90 (0.78-1.04)	1.05 (0.97-1.14)
Number of other medications in 2004	<b>1.01 (1.00-1.01)</b>	<b>1.07 (1.05-1.08)</b>	<b>1.04 (1.04-1.04)</b>
Statin MPR 2004	<b>0.98 (0.98-0.98)</b>	<b>0.99 (0.98-0.99)</b>	<b>0.97 (0.97-0.97)</b>

Note: Tests were considered significantly different if  $p < 0.0167$  (after Bonferroni adjustment). For concessional beneficiaries the model was also adjusted for individuals who held a Department of Veteran Affairs health care card as a binary variable.

IHD = ischemic heart disease.

CARP=coronary artery revascularisation procedure.

PDC=Proportion of days covered.

MPR=Medication Possession Ratio.

Table 2A: Unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for reduction compared with continuation of therapy among individuals dispensed a statin in 2005 stratified by beneficiary status.

Reduction in therapy (>20% reduction in PDC from 2004 to 2005)			
Demographic and clinical characteristics	Unadjusted OR (95%CI)	Adjusted OR (95%CI) – general patients	Adjusted OR (95%CI) – Concessional patients
Age:			
40 & below	<b>2.82 (2.59-3.08)</b>	<b>2.07 (1.50-2.85)</b>	<b>2.30 (2.01-2.64)</b>
41 to 50	<b>1.88 (1.78-2.00)</b>	<b>1.57 (1.15-2.14)</b>	<b>1.69 (1.54-1.84)</b>
51 to 60	<b>1.31 (1.21-1.38)</b>	1.28 (0.94-1.74)	<b>1.14 (1.07-1.22)</b>
61 to 70	<b>0.85 (0.81-0.90)</b>	1.09 (0.80-1.48)	<b>0.82 (0.78-0.87)</b>
71 to 80	<b>0.79 (0.75-0.83)</b>	0.99 (0.71-1.38)	<b>0.81 (0.77-0.86)</b>
Above 80	1	1	1
Sex:			
Female	0.97 (0.95-0.99)	<b>1.06 (1.01-1.11)</b>	1.03 (0.99-1.06)
Male	1	1	1
Socio-economic disadvantage:			
Most (1)	<b>1.06 (1.01-1.11)</b>	<b>1.25 (1.13-1.38)</b>	<b>1.08 (1.02-1.15)</b>
2	0.98 (0.95-1.02)	<b>1.18 (1.09-1.27)</b>	1.03 (0.98-1.09)
3	<b>0.94 (0.91-0.98)</b>	<b>1.09 (1.02-1.17)</b>	0.98 (0.94-1.04)
4	0.98 (0.94-1.02)	1.02 (0.96-1.09)	1.02 (0.97-1.08)
Least (5)	1	1	1
Unknown	1.10 (0.99-1.22)	1.10 (0.95-1.27)	0.91 (0.76-1.08)
Remoteness			
Major cities	1	1	1
Inner regional	<b>0.91 (0.88-0.95)</b>	<b>0.87 (0.81-0.94)</b>	0.98 (0.94-1.02)
Outer regional	1.05 (1.00-1.09)	0.92 (0.85-0.99)	1.04 (0.99-1.10)
Remote	<b>1.12 (1.03-1.22)</b>	0.90 (0.79-1.02)	1.09 (0.96-1.23)
Very remote	<b>1.53 (1.31-1.78)</b>	0.99 (0.78-1.25)	<b>1.56 (1.27-1.92)</b>
Unknown	1.17 (0.77-1.79)	1.01 (0.55-1.86)	1.20 (0.62-2.32)
Previous IHD (2000-2004):			
No	<b>1.14 (1.09-1.19)</b>	1.01 (0.89-1.15)	1.02 (0.95-1.09)
Yes	1	1	1
Previous Stroke (2000-2004):			
No	1.09 (0.97-1.23)	0.81 (0.60-1.09)	1.09 (0.95-1.25)
Yes	1	1	1
Previous CARP (2000-2004):			
No	<b>1.14 (1.07-1.21)</b>	1.04 (0.88-1.22)	1.09 (0.99-1.20)
Yes	1	1	1

Previous Statin Usage in 2002 and 2003:			
No	<b>2.52 (2.43-2.60)</b>	<b>2.40 (2.27-2.53)</b>	<b>2.27 (2.17-2.38)</b>
Yes	1	1	1
Beneficiary Status:			
Concessional	1	-	-
General	<b>1.56 (1.51-1.60)</b>	-	-
Cardiovascular Medication in 2004			
Yes	1	1	1
No	<b>1.58 (1.53-1.62)</b>	<b>1.34 (1.27-1.41)</b>	<b>1.27 (1.22-1.32)</b>
Diabetic Medication in 2004			
Yes	1	1	1
No	<b>1.13 (1.09-1.17)</b>	<b>1.19 (1.08-1.31)</b>	1.02 (0.98-1.07)
Number of other medications in 2004	<b>0.99 (0.98-0.99)</b>	1.00 (0.99-1.01)	<b>1.02 (1.01-1.02)</b>
Statin MPR 2004	<b>0.99 (0.99-0.99)</b>	<b>0.99 (0.99-0.99)</b>	<b>0.99 (0.99-0.99)</b>

Note: Tests were considered significantly different if  $p < 0.0167$  (after Bonferroni adjustment). For concessional beneficiaries the model was also adjusted for individuals who held a Department of Veteran Affairs health care card as a binary variable.

IHD=ischemic heart disease.

CARP=coronary artery revascularisation procedure.

PDC=Proportion of Days Covered.

MPR=Medication Possession Ratio.

